Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule
Lam B, Ito S, Ryu J, O'Sullivan K, Potnis K, Lu R, Bidikian A, Freed J, La J, Goshua G. Identifying Patients with Erythrocytosis Not Requiring JAK2 Testing: External Validation and Decision Analysis of the Jakpot Prediction Rule. Blood 2024, 144: 3669-3669. DOI: 10.1182/blood-2024-198033.Peer-Reviewed Original ResearchNegative predictive valueBeth Israel Deaconess Medical CenterClinical prediction rulePolycythemia veraIncremental net monetary benefitHealth resource utilizationPV patientsMyeloproliferative neoplasmsVA cohortTest characteristicsUS health system perspectivePrediction ruleAssociated with increased riskNon-fatal cardiovascular eventsExternal validation cohortAssociated with increased risk of strokeRandomized trial dataMarkov cohort modelLifetime time horizonProbabilistic sensitivity analysesRisk of strokePersistent erythrocytosisMedian ageHematologic malignanciesDiagnostic workupCost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC)
Merz L, Ito S, Walkovich K, Achebe M, Van Havre N, Frustace P, Goshua G. Cost-Effectiveness of Universal Duffy Testing at 9-12 Months: An Effort Towards Equity in Interpreting Absolute Neutrophil Counts (ANC). Blood 2024, 144: 162. DOI: 10.1182/blood-2024-202605.Peer-Reviewed Original ResearchIncremental net monetary benefitAbsolute neutrophil countWork-upBirth cohortBase-caseCenters for Medicare & Medicaid ServicesMitigate patient harmCost-effective strategyUniversal testingUS health system perspectiveThreshold sensitivity analysisDiscounted quality-adjusted life yearsInfectious work-upHealth system perspectiveNo testBone marrow biopsyIncreased risk of infectionCross-sectional studyAnti-neutrophil antibodiesDiagnostic work-upQuality-adjusted life yearsUniversal testing strategiesUnited StatesCost-effectiveMarkov cohort model